Drug intelligence / Profile preview

CUCART19

Development stage: Phase 2
Lead developer: Allogene Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CUCART19 is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of B-cell malignancies. It targets CD19, a protein expressed on B cells, enabling modified T cells to recognize and destroy CD19-expressing cancer cells.

Other names: Anti-CD19 CAR-T (Hong Kong Children's Hospital)

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CUCART19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUCART19.

Explore the full profile